Abstract：
BACKGROUND: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO). The aim of this study was to assess the impact of an FAc intravitreal implant on intraocular pressure (IOP).
METHODS: We retrospectively collected anonymised data on the patients\' characteristics, DMO treatment, and IOP and IOP-lowering treatments before and after the FAc intravitreal implant between September 2013 and March 2020 in several European centres.
RESULTS: A total of 221 eyes from 179 patients were included. The mean follow-up duration was 13.4 (± 12.5, range 2.4-33.5) months. Overall, 194 eyes (88.2%) had received an intravitreal dexamethasone injection before the FAc intravitreal implant. For 25 eyes (11.3%) there was a history of glaucoma, and 52 eyes (23.5%) had previous IOP-lowering treatment. Mean IOP before injection was 14.7 (3.4) mmHg and increased to 16.9 (3.7) mmHg 12 months after injection (P < 0.0001). During follow-up, 55 eyes (24.9%) required the addition or initiation of topical IOP-lowering medication, only one patient (0.5%) had laser trabeculoplasty and one patient (0.5%) a minimally invasive glaucoma surgery, and no patient required incisional IOP-lowering surgery.
CONCLUSIONS: The FAc intravitreal implant led to substantial IOP elevation. This elevation was monitored most of the time with addition or initiation of topical IOP-lowering medication.
METHODS: We retrospectively collected anonymised data on the patients\' characteristics, DMO treatment, and IOP and IOP-lowering treatments before and after the FAc intravitreal implant between September 2013 and March 2020 in several European centres.
RESULTS: A total of 221 eyes from 179 patients were included. The mean follow-up duration was 13.4 (± 12.5, range 2.4-33.5) months. Overall, 194 eyes (88.2%) had received an intravitreal dexamethasone injection before the FAc intravitreal implant. For 25 eyes (11.3%) there was a history of glaucoma, and 52 eyes (23.5%) had previous IOP-lowering treatment. Mean IOP before injection was 14.7 (3.4) mmHg and increased to 16.9 (3.7) mmHg 12 months after injection (P < 0.0001). During follow-up, 55 eyes (24.9%) required the addition or initiation of topical IOP-lowering medication, only one patient (0.5%) had laser trabeculoplasty and one patient (0.5%) a minimally invasive glaucoma surgery, and no patient required incisional IOP-lowering surgery.
CONCLUSIONS: The FAc intravitreal implant led to substantial IOP elevation. This elevation was monitored most of the time with addition or initiation of topical IOP-lowering medication.
摘要：
背景：0.19mg醋酸氟轻松（FAc）玻璃体内植入物可连续注射皮质类固醇，用于治疗难治性糖尿病性黄斑水肿（DMO）。这项研究的目的是评估FAc玻璃体内植入物对眼内压（IOP）的影响。
方法：我们回顾性收集了患者特征的匿名数据，DMO治疗,以及2013年9月至2020年3月期间在几个欧洲中心进行的FAc玻璃体内植入前后的IOP和降IOP治疗。
结果：共纳入179例患者的221只眼。平均随访时间为13.4（±12.5，范围2.4-33.5）个月。总的来说,194只眼(88.2%)在FAc玻璃体内植入前接受了玻璃体内注射地塞米松。25眼（11.3%）有青光眼病史，52眼（23.5%）曾接受过降低IOP治疗。注射前平均IOP为14.7（3.4）mmHg，注射后12个月增加至16.9（3.7）mmHg（P<0.0001）。随访期间,55只眼睛（24.9%）需要添加或开始局部降眼压药物，只有一名患者（0.5％）进行了激光小梁成形术，一名患者（0.5％）进行了微创青光眼手术，并且没有患者需要进行降低IOP的手术。
结论：FAc玻璃体内植入导致IOP显著升高。在添加或开始局部IOP降低药物的情况下，大多数时间都会监测这种升高。
方法：我们回顾性收集了患者特征的匿名数据，DMO治疗,以及2013年9月至2020年3月期间在几个欧洲中心进行的FAc玻璃体内植入前后的IOP和降IOP治疗。
结果：共纳入179例患者的221只眼。平均随访时间为13.4（±12.5，范围2.4-33.5）个月。总的来说,194只眼(88.2%)在FAc玻璃体内植入前接受了玻璃体内注射地塞米松。25眼（11.3%）有青光眼病史，52眼（23.5%）曾接受过降低IOP治疗。注射前平均IOP为14.7（3.4）mmHg，注射后12个月增加至16.9（3.7）mmHg（P<0.0001）。随访期间,55只眼睛（24.9%）需要添加或开始局部降眼压药物，只有一名患者（0.5％）进行了激光小梁成形术，一名患者（0.5％）进行了微创青光眼手术，并且没有患者需要进行降低IOP的手术。
结论：FAc玻璃体内植入导致IOP显著升高。在添加或开始局部IOP降低药物的情况下，大多数时间都会监测这种升高。
